Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: 1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
Paricalcitol is supplied as a crystalline solid. A stock solution may be made by dissolving the paricalcitol in the solvent of choice. Paricalcitol is soluble in organic solvents such as ethanol, which should be purged with an inert gas. The solubility of paricalcitol in ethanol is approximately 1 mg/ml. Paricalcitol is slightly soluble in acetone, chloroform, and DMSO. Paricalcitol is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.
Sudsakorn, S., Phatarphekar, A., O’Shea, T., et al. Determination of 1,25-dihydroxyvitamin D2 in rat serum using liquid chromatography with tandem mass spectrometry. J. Chromatogr. B 879, 139-145 (2011).
Kato, S., Kim, M.-S., Yamaoka, K., et al. Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D. Curr. Opin. Nephrol. Hypertens. 16, 297-304 (2007).
Brown, A.J., Finch, J., Takahashi, F., et al. Calcemic activity of 19-nor-1,25(OH)2D2 decreases with duration of treatment. J. Am. Soc. Nephrol. 11, 2088-2094 (2000).
Donate-Correa, J., Domínguez-Pimentel, V., Muros-de-Fuentes, M., et al. Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease. Curr. Drug Targets 15, 703-709 (2014).
Walf, M. and Thadhani, R. Vitamin D in patients with renal failure: A summary of observational mortality studies and steps moving forward. J. Steroid Biochem. Mol. Biol. 103(3-5), 487-490 (2007).